Abstract
The present research has been carried out to elicit the mechanism of antiangiogenic activity of a fusion peptide P2. Peptide P2 was designed by the connection of a heptapeptide MMP inhibitor to ES-2, a fragment of Endostatin. In a previous study, P2 demonstrated strong antiangiogenic and antitumor effect, and the current work explains the antiangiogenic mechanism of P2 through endothelial cell proliferation and apoptosis. In our study, it was shown that P2 inhibited HUVECs proliferation at a low serum concentration and this effect might be achieved through arresting cell cycle by decreasing the expression level of Cyclin D1. In addition, P2 was found to induce apoptosis of HUVECs. Using Western blot, it was indicated that P2 induced the cleavage of Caspase-3, the hallmark protease of apoptosis. The activation and expression of the upstream regulator Caspase-9 can also be affected by P2 treatment. Furthermore, P2 reduced the protein level of antiangiogenic factors Bcl-xL and Bcl-2. These results revealed that P2 regulates endothelial cell apoptosis through intrinsic apoptotic pathway.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Addison CL, Nor JE, Zhao H, Linn SA, Polverini PJ, Delaney CE (2005) The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent BMC cell biology 6:38. https://doi.org/10.1186/1471-2121-6-38
Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP (2007) Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104:20262–20267. https://doi.org/10.1073/pnas.0706438104
Basset P et al (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699–704. https://doi.org/10.1038/348699a0
Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574–578
Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA (1992) Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 16:500–507
Dallas SL, Rosser JL, Mundy GR, Bonewald LF (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277:21352–21360. https://doi.org/10.1074/jbc.M111663200
Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP (1999) Endostatin induces endothelial cell apoptosis. J Biol Chem 274:11721–11726
Dixelius J et al (2000) Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95:3403–3411
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186. https://doi.org/10.1056/nejm197111182852108
Folkman J (2006a) Angiogenesis. Annu Rev Med 57:1–18. https://doi.org/10.1146/annurev.med.57.121304.131306
Folkman J (2006b) Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res 312:594–607. https://doi.org/10.1016/j.yexcr.2005.11.015
Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G (1995) Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 62:407–413
Hanai J et al (2002) Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 277:16464–16469. https://doi.org/10.1074/jbc.M112274200
Ikeda M et al (2000) Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clin Cancer Res Off J Am Assoc Can Res 6:3290–3296
Koivunen E et al (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768–774. https://doi.org/10.1038/11703
Mohajeri A, Sanaei S, Kiafar F, Fattahi A, Khalili M, Zarghami N (2017) The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering. Adv Pharmaceut Bull 7:21–34. https://doi.org/10.15171/apb.2017.004
Muller D et al (1991) Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 48:550–556
O’Reilly MS et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285
Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657–672. https://doi.org/10.1038/nrc884
Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT (1991) Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117:144–150
Qiu Z et al (2012) Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-alpha converting enzyme (TACE/ADAM-17). J Enzyme Inhib Med Chem 27:533–540. https://doi.org/10.3109/14756366.2011.599323
Qiu Z, Hu J, Xu H, Wang W, Nie C, Wang X (2013) Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment. Anticancer Drugs 24:677–689. https://doi.org/10.1097/CAD.0b013e328361b7ad
Reis RC, Schuppan D, Barreto AC, Bauer M, Bork JP, Hassler G, Coelho-Sampaio T (2005) Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. Biochem Biophys Res Commun 333:976–983. https://doi.org/10.1016/j.bbrc.2005.06.011
Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516. https://doi.org/10.1146/annurev.cellbio.17.1.463
Vandooren J et al (2015) Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1. Biochem J 465:259–270. https://doi.org/10.1042/bj20140418
Wang J et al (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer 8:283–290. https://doi.org/10.3779/j.issn.1009-3419.2005.04.07
Wickstrom SA, Alitalo K, Keski-Oja J (2004) An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 279:20178–20185. https://doi.org/10.1074/jbc.M312921200
Xu HM et al (2008) An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo. Bioconjugate Chem 19:1980–1986. https://doi.org/10.1021/bc800132p
Yadav L, Puri N, Rastogi V, Satpute P, Sharma V (2015) Tumour angiogenesis and angiogenic inhibitors: a review. JCDR 9:Xe01–Xe05. https://doi.org/10.7860/jcdr/2015/12016.6135
Yuan S et al (2008) Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis. FASEB J Off Publ Fed Am Soc Exp Biol 22:2809–2820. https://doi.org/10.1096/fj.08-107417
Acknowledgements
The present study was supported by the National Natural Science Foundation of China (Grant Nos. 81301902 and 81773837) and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interests regarding the publication of this paper.
Informed consent
All authors read and approved the final manuscript.
Additional information
Handling Editor: G. J. Peters.
Rights and permissions
About this article
Cite this article
Xu, Y., Qiang, X., Xing, L. et al. A fusion antitumor peptide regulates proliferation and apoptosis of endothelial cells. Amino Acids 50, 1121–1129 (2018). https://doi.org/10.1007/s00726-018-2589-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-018-2589-4